Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers
Related Experiment Video
Updated: Jun 8, 2026
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
1Department of Medical Oncology, National Cancer Centre, Singapore 169610.
Abstract:
An understanding of the mutations of the proto-oncogenes and tumor suppressor genes that occur in thyroid cancers should eventually explain the diverse clinical characteristics of these tumors and also direct therapy. Some insights have already emerged in the last decade; some abnormalities in tumor genes are consistently associated with specific clinical and pathologic findings. These genetic abnormalities usually represent somatic mutations in tumors of follicular epithelial origin, as opposed to inherited mutations in medullary thyroid cancers of parafollicular C cells origin because most thyroid tumors are sporadic and not familial. This is different from the multiple endocrine neoplasia syndromes in which the primary tumorigenic gene mutations are inherited. This improved understanding of the molecular basis of these diseases has led to the development of novel targeted therapeutic approaches which will be discussed in this paper.
Insights
Understanding gene mutations in thyroid cancer explains diverse tumor characteristics and guides targeted therapies. Most thyroid tumors have somatic mutations, unlike inherited mutations in rare familial syndromes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Thyroid cancers exhibit diverse clinical and pathological features.
- Proto-oncogenes and tumor suppressor genes are critical in thyroid tumorigenesis.
- Understanding genetic mutations is key to explaining tumor heterogeneity and directing treatment.
Purpose of the Study:
- To elucidate the role of gene mutations in thyroid cancer.
- To correlate specific genetic abnormalities with clinical and pathological findings.
- To discuss the development of targeted therapies based on molecular understanding.
Main Methods:
- Analysis of somatic mutations in follicular epithelial thyroid tumors.
- Distinguishing somatic mutations from inherited mutations (e.g., in Multiple Endocrine Neoplasia syndromes).
- Review of current literature on genetic alterations in thyroid cancer.
Main Results:
- Specific gene abnormalities are consistently linked to distinct clinical and pathological features.
- Most thyroid tumors arise from somatic mutations in follicular cells.
- Medullary thyroid cancers of C-cell origin may involve inherited mutations.
Conclusions:
- Molecular insights into thyroid cancer genetics are advancing.
- Understanding somatic mutations in thyroid cancer is crucial for personalized therapy.
- Targeted therapeutic strategies are emerging based on these genetic discoveries.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...